Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | Varying efficacies of combination and monotherapies in CLL

Alessandra Tedeschi and Constantine Tam • 21 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Chlorambucil Ibrutinib Obinutuzumab Venetoclax

Alessandra Tedeschi, MD, Niguarda Cancer Center, Milan, Italy, and Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, speaking at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK. The speakers discuss a variety of novel therapies in chronic lymphocytic leukemia (CLL) treatment and compare the efficacies and limitations of these treatments in patients. The speakers also touch on the genetic screening of patients in order to better predict responses to treatment.

More from Alessandra Tedeschi

1:20
RESONATE-2: Ibrutinib for CLL 5-year follow-up
Alessandra Tedeschi • 21 Sep 2019
1:25
iLLUMINATE 4-year follow up: obinutuzumab w/ ibrutinib vs w/ chlorambucil
Alessandra Tedeschi • 22 Sep 2019
1:52
RESONATE: five-year follow-up of ibrutinib for CLL
Alessandra Tedeschi • 15 Jun 2019
2:44
Waldenström’s Macroglobulinemia: frontline treatment
Alessandra Tedeschi • 15 Jun 2019

More from Constantine Tam

1:13
ALPINE trial update: zanubrutinib continues to show superior efficacy to ibrutinib in CLL
Constantine Tam • 11 Dec 2023
2:06
The potential of BGB-16673, a BTK degrader, for the treatment of R/R B-cell malignancies
Constantine Tam • 11 Dec 2023
1:52
SYMPATICO: Primary analysis results of ibrutinib plus venetoclax for patients with R/R MCL
Constantine Tam • 11 Dec 2023
2:36
Sonrotoclax plus zanubrutinib combination shows promise in treatment-naïve CLL/SLL
Constantine Tam • 11 Dec 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals